Decreased expression of the mannose 6- phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells by Chen, Zhihong et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Cancer
BMC Cancer  2002,  2 x Research article
Decreased expression of the mannose 6- phosphate/insulin-like 
growth factor-II receptor promotes growth of human breast cancer 
cells
Zhihong Chen, Yinlin Ge, Natalie Landman and Jing X Kang*
Address: Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114
E-mail: Zhihong Chen - j8018@yahoo.com; Yinlin Ge - yge@partners.org; Natalie Landman - talichka@yahoo.com; 
Jing X Kang* - Kang.jing@mgh.harvard.edu
*Corresponding author
Abstract
Background: Loss or mutation of the mannose 6-phosphate/insulin-like growth factor-II receptor
(M6P/IGF2R) has been found in breast cancer. However, whether or not decreased levels of
functional M6P/IGF2R directly contribute to the process of carcinogenesis needs to be further
verified by functional studies.
Methods: In this study, using viral and ribozyme strategies we reduced the expression of M6P/
IGF2R in human breast cancer cells and then examined the effect on growth and apoptosis of these
cells.
Results: Our results showed that infection of MCF-7 cells with the adenovirus carrying a ribozyme
targeted against the M6P/IGF2R mRNA dramatically reduced the level of transcripts and the
functional activity of M6P/IGF2R in these cells. Accordingly, cells treated with the ribozyme
exhibited a higher growth rate and a lower apoptotic index than control cells (infected with a
control vector). Furthermore, decreased expression of M6P/IGF2R enhanced IGF-II-induced
proliferation and reduced cell susceptibility to TNF-induced apoptosis.
Conclusions: These results suggest that M6P/IGF2R functions as a growth suppressor and its loss
or mutation may contribute to development and progression of cancer. This study also
demonstrates that adenoviral delivery of the ribozyme provides a useful tool for investigating the
role of M6P/IGF2R in regulation of cell growth.
Background
With one million new cases each year, breast cancer is the
most common cancer among women and is the leading
cause of death in women 30 to 70 years of age in the
world. Breast cancer results from genetic and environmen-
tal factors including diet, radiation and hormones [1–5].
The molecular events involved in breast carcinogenesis,
however, remain to be elucidated.
Numerous studies have shown that polypeptide growth
factors such as insulin-like growth factors (IGFs) are mi-
togens for breast cancer cells [6–9]. The IGF-I and IGF-II
signal through a common tyrosine kinase receptor, the in-
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sulin-like growth factor 1 receptor (IGF1R), and have mi-
togenic and cell survival actions that may promote tumor
development. Modulation of this mitogenic pathway oc-
curs in part via the M6P/IGF2R, which functions in the in-
ternalization and degradation of IGF-II [10]. M6P/IGF2R
is also important in activation of TGF-, a potent growth
inhibitor for most cell types, and in binding, transport
and activation of lysosomal enzymes, such as cathepsins
[12,13]. It has been shown that M6P/IGF2R expression is
significantly reduced in both rat and human hepatocellu-
lar carcinomas [14]. Loss of hetorozygosity (LOH) at the
M6P/IGF2 receptor gene locus on 6q26-27 coupled with
somatic point mutations in the remaining allele has re-
cently been demonstrated in liver and breast cancers [15–
23]. In addition, somatic mutations of the M6P/IGF2R
gene were also found in prostate cancer, lung carcinoma,
and genetically unstable cancers of the endometrium,
brain, stomach and colorectum [24–29]. The findings of
LOH and mutations of M6P/IGF2R in a wide variety of tu-
mor types have led to the proposition that the M6P/IGF2R
is a tumor suppressor gene. In addition to genetic data, a
tumor suppressor gene candidate has to meet functional
criteria. The functional characteristics of a tumor suppres-
sor gene have not been well established for M6P/IGF2R.
Thus, further studies that address the relationship be-
tween the functional M6P/IGF2R level and cell growth ac-
tivity are needed.
To verify whether decreased levels of functional M6P/
IGF2R can provide a growth advantage for cancer cells, we
used viral and ribozyme strategies to reduce the expres-
sion of M6P/IGF2R in human breast cancer cells and then
examined the effect on growth and apoptosis of these
cells.
Methods
Construction of a recombinant adenoviral vector contain-
ing the M6P/IGF2R-ribozyme
A 49 bp M6P/IGF2R ribozyme oligonucleotide, 5'-GAAT-
TCTCCACACTGATGAGCCGCTTCGGCGGCGAAACAT-
TCAACGCGT-3' and the corresponding reverse
complementary strand were synthesized. The fragments
were subcloned into pRz951 to produce a plasmid (desig-
nated as pRz-IGF2R) containing a ribozyme targeted
against the M6P/IGF2R. For construction of the recom-
binant adenovirus containing the M6P/IGF2R-ribozyme
(pAd-GFP/Rz-IGF2R), the segments containing the ri-
bozymes were amplified by PCR and cloned into a
pAdTrack-CMV vector and then recombined homolo-
gously with an adenoviral backbone pAdEasy 1 vector to
generate pAd-GFP/Rz-IGF2R, following the protocol de-
scribed by He et al [30]. The pAd-GFP/Rz-IGF2R carries
both the Rz-IGF2R and GFP (as reporter) genes, each un-
der the control of separate cytomegalovirus (CMV) pro-
moters. Another viral vector, pAd-GFP, which carries the
GFP gene only under the control of the CMV promoter,
was generated and used as a control vector. The adenoviral
vector DNA were linerized with Pac I and transfected into
the replication-permissive 293 cells (E1A transcomple-
menting cell line) using Lipofectamine (Life Technolo-
gies) to produce E1-deleted, replication-defective
recombinant adenovirus as described previously [30].
Large-scale amplification of the recombinant adenovirus
in 293 cells was followed by purification using a discon-
tinuous CsCl gradient. The constructs were confirmed by
enzymatic digestion and DNA sequencing.
Transcription and cleavage reaction of the ribozyme in vit-
ro
Plasmids containing the ribozyme or the substrate (either
45 bp of M6P/IGF2R mRNA or an unmatched sequence
Figure 1
Hammerhead ribozyme structure and target sequence of the
M6P/IGF2R mRNA (A) and ribozyme activity against M6P/
IGF2R RNA in vitro (B). 32P-labeled RNA (40 nM) containing
the M6P/IGF2R target sequence was incubated with the ham-
merhead ribozyme (60 nM) and the reaction products were
separated on a polyacrylamide gel. The ribozyme cleaves the
M6P/IGF2R target efficiently in vitro. Lane 1: Unmatched tar-
get alone; Lane 2: Unmatched target incubation with
ribozyme at 12 hours; Lane 3: Specific target alone; Lane 4:
Specific target incubation with ribozyme at time 0; Lane 5–7:
Specific target incubation with ribozyme at 1, 2 and 12 hours.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/18
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5'-ATATTGTCCAGTGC-3') were linearized with Mlu I. All
transcripts were generated with T7 RNA polymerase
(Promega). Substrate transcripts were labeled by incorpo-
ration of [32P]UTP (10 Ci/ml; Nen Life Science Products,
Inc.). Specific activity of the [32P]UTP and the base com-
position of each substrate molecule were used to calculate
substrate concentration. Ribozyme transcripts were quan-
tified spectrophotometrically. Cleavage reactions con-
tained 30 nM substrate RNA, increasing amounts (60 nM)
of ribozyme, 20 mM MgCl2 and 20 mM Tris-HCl (pH
8.0), 1 l DTT, and 1 l RNA inhibitor in a final volume
of 10 l. Cleavage reactions were incubated at 37C for 2
hrs. Reactions were stopped by addition of loading buffer:
80% formamide, 10 mM Na2EDTA (pH 8.0), and 1 mg/
ml each bromophenol blue and xylene cyanol. Cleavage
products were analyzed on 15% polyacrylamide and 8 M
urea denaturing gels. NIH Imager was used to quantitate
product and substrate fragments.
Cell cultures and infection with Ad-GFP/IGF2R-Rz and Ad-
GFP
MCF-7 cells were cultured in DMEM medium containing
10% FBS at 37C in a tissue culture incubator with 5%
CO2 and 98% relative humidity. Cells were used for ex-
periments after 2–3 days in culture. Viral infections were
carried out by adding viral particles at various concentra-
tions (usually, 2  108 virus particles/ml) to culture medi-
um containing 2% FBS. Initially, optimal viral
concentration was determined by using Ad-GFP to
achieve an optimal balance of high gene expression and
low viral titer to minimize cytotoxicity. After 24 hrs of in-
cubation, the infection medium was replaced with normal
(10% FBS) culture medium. For treatment with IGF-II,
cells were incubated with 50 ng/ml IGF-II after infection
with Ad-GFP/IGF2R-Rz or Ad-GFP. Seventy two hrs post
infection, cells were used for analysis of M6P/IGF2R gene
expression and its effect on cell growth.
Analysis of M6P/IGF2R gene expression in MCF-7 cells
The M6P/IGF2R transcripts were determined by RT-PCR
using the GeneAmp EZ rTt RNA PCR kit (Roche). Total
RNA was extracted from cultured cells using an RNA iso-
lation kit (Qiagen), according to the manufacturer's pro-
tocol. M6P/IGF2R transcripts were amplified using
primers 5'-GACAGGCTTGTCCTGAGTTA-3' and 5'-TTCT-
GCTCTGGTTCTGCATG 3', specific to the M6P/IGF2R re-
ceptor. Each RT-PCR assay was performed in triplicate.
Primers specific for human -actin cDNA were added to a
parallel reaction to standardize for variations in PCR be-
tween samples. PCR products were resolved on a 1.0 %
agarose gel, visualized under UV light and quantitated us-
ing NIH Imager.
Measurement of 125I -IGF-II internalization
Cells were incubated at 37C for 2 hrs in serum-free
DMEM containing 125I-labeled IGF-II (0.5 ng/ml) with or
without excess unlabeled IGF-II (2 g/ml). Following the
incubation, the cells were washed three times with ice-
cold PBS, and cell-associated radioactivity was deter-
mined by a -counter. Specific internalized 125I-IGF-II was
calculated by subtracting the counts of samples with ex-
cessive unlabeled IGF-II from that without unlabeled IGF-
II, and normalized to protein content.
Beta-glucuronidase binding assay
Binding of -glucuronidase was assayed as described pre-
viously [31,32]. Briefly, cells were permeabilized with
0.25% saponin in 50 mM Hepes (pH 7.0), 150 mM NaCl,
5 mM -glycerophosphate, 0.5% human serum albumin,
and 10 mM mannose-6-phosphate (M6P) for 30 minutes
on ice. The cells were washed three times with ice-cold
PBS containing 0.05% saponin. They were incubated with
20,000 units/ml -glucuronidase from bovine liver (Sig-
ma) in 50 mM Hepes (pH 7.5) containing 150 mM NaCl,
Figure 2
RT-PCR detection of the M6P/IGF2R ribozyme expressed in
MCF-7 cells. MCF-7 cells were infected with Ad.GFP.Rz-
IGF2R or Ad.GFP. Seventy two hrs post infection, cells were
collected and total RNA extracted. The presence of the
ribozyme was detected by RT-PCR using primers specific to
the ribozyme. Lane 1: Cells infected with Ad.GFP; Lane 2:
cells infected with Ad.GFP.Rz-IGF2R.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/18
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5 mM -glycerophosphate, 0.5% human serum albumin,
0.5% saponin with or without 10 mM M6P overnight on
ice. Cells were washed five times with ice-cold PBS con-
taining 0.05% saponin and sonicated in 100 mM sodium
acetate (pH 4.6). The protein concentration of solubilized
cell extract was measured and enzyme activity was assayed
as follows: for each reaction 50 l cell extract were added
to 500 l of 100 mM sodium acetate (pH 4.0) containing
1 mM paranitrophenyl (PNP)--glucuronide (Sigma) as
substrate. After an incubation period of 3 hours at 37C,
500 l 1 M Na2CO3 were added to each reaction and the
absorbance was measured at 400 nm. Experimental values
were compared to a standard curve that was constructed
using 1–100 nM solutions of PNP (Sigma) in 500 l 100
mM sodium acetate and 500 l 1 M Na2CO3. Specific ac-
tivity was calculated as nM of PNP produced/hour/mg of
protein.
Beta-glucuronidase endocytosis assay
Beta-glucuronidase endocytosis assay was carried out as
described previously [33]. Briefly, confluent cell cultures
were washed twice with pre-warmed serum-free DMEM
followed by incubation with DMEM containing 5 mg/ml
human serum albumin and 10 mM M6P for 20 minutes.
Following incubation cells were washed 3 times with pre-
warmed DMEM. Cells were then incubated in DMEM con-
taining 5 mg/ml human serum albumin alone or 4000
units -glucuronidase with or without 10 mM M6P for 2
hours at 37C. Following the incubation, the cells were
washed 5 times with ice-cold PBS and subjected to en-
zyme activity assay as described above.
Cell proliferation assay (MTT assay and cell counting)
MCF-7 cells were grown in culture plates (tissue culture
grade, 12 wells, flat bottom) in a final volume of 1 ml se-
rum-containing culture medium per well, in a humidified
atmosphere at 37C and 5% CO2 for 3 days. After infec-
tion with Ad-GFP/IGF2R-Rz or Ad-GFP, cells were incu-
bated with or without 50 ng/ml IGF-II for 4 days. 100 l
MTT labelling reagent were added to each well and incu-
bated for 4 hrs, followed by addition of 1 ml solubiliza-
tion solution into each well. The cells were incubated at
37C overnight. Spectrophotometrical absorbency of the
samples was measured using an UV-visible Recording
Spectrophotometer with wavelength of 550–690 nm. In
addition, the total number of viable cells in each treat-
ment group was counted by a trypan blue exclusion meth-
od using a hemocytometer.
Analysis of cell apoptosis
MCF-7 cells were infected with Ad-GFP or Ad-GFP/Rz-
IGF2R. Seventy two hrs post infection, cells were treated
with TNF (0.1 ng/ml) for 24 hrs. Apoptotic cells were
identified by Hoechst staining using the Vybrant™ Apop-
tosis Kit #5 (Molecular Probes) according to the manufac-
turer's protocol. In addition, after infection with Ad-GFP
or Ad-GFP/Rz-IGF2R and treatment with TNF, cell viabil-
ity was assessed using the MTT assay Kit (Roche Molecular
Biochemicals) and cell apoptosis was determined using
the Cell Death Detection ELISA Kit assay (Roche Molecu-
lar Biochemicals) according to the manufacturer's proto-
col.
Figure 3
Effect of the ribozyme on the level of M6P/IGF2R mRNA in
MCF-7 cells. A: a representative RT-PCR result showing the
levels of M6P/IGF2R (lanes 3 and 4) and the corresponding
amounts of -actin mRNA (lane 1 and 2) in ribozyme-treated
(lane 1, lane 3) and in control cells (lane 2, lane 4). B: bar
chart showing percent change in M6P/IGF2R mRNA of
ribozyme-treated cells relative to the mRNA fraction in con-
trol cells (normalized to -actin). Total RNA was isolated
from cultured MCF-7 cells infected with Ad.GFP/Rz-IGF2R
or Ad.GFP for 72 hrs, and then subjected to RT-PCR using
M6P/IGF2R specific primers and -actin as an internal stand-
ard. The data are the mean  SE of three separate experi-
ments (n = 3, *, p < 0.05 versus control).BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/18
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Statistical analysis
Students's t-test was used to evaluate the difference be-
tween two values. Each experiment was repeated at least
three times. Statistical significance was accepted at the lev-
el of p < 0.05.
Results
Cleavage reaction of the ribozyme in vitro
The M6P/IGF2R ribozyme we constructed has 13-bp
binding arms complementary to the target site of M6P/
IGF2R mRNA, and a catalytic core (Fig. 1A). To evaluate
the bioactivity/specificity of the ribozyme and the accessi-
bility of the target site, a cleavage reaction in vitro was per-
formed. The substrates, [-32P] labeled RNA transcripts
containing 45 bp of M6P/IGF2R mRNA or an unmatched
sequence, were incubated with the ribozyme as described
(see Materials and Methods). The ribozyme cleaved only
the M6P/IGF2R mRNA into the expected products. In this
assay, the hammerhead ribozyme was able to cleave about
50% of the M6P/IGF2R target within 2 hr of incubation,
and by 12 hrs, more than 90% of the M6P/IGF2R target
was converted to the expected products (Fig. 1B). These re-
sults indicate a high efficiency and specificity of the ri-
bozyme in vitro.
Expression of the M6P/IGF2R-ribozyme in cultured MCF-7 
cells
To test whether infection of cultured cells with the Ad-
GFP/Rz-IGF2R can induce the expression of the ribozyme
(Rz-IGF2R), total RNA was extracted from cells infected
with Ad-GFP/IGF2R-Rz or Ad-GFP, and subjected to RT-
PCR using ribozyme-specific primers. As shown in Fig. 2,
infection of MCF-7 cells with Ad-GFP/Rz-IGF2R resulted
in positive expression of the ribozyme as determined by
RT-PCR. As expected, the ribozyme sequence-specific
primers produced a 430-bp PCR fragment only in cells in-
fected with Ad-GFP/Rz-IGF2R, but not in cell infected
with the control viral vector Ad-GFP.
Ribozyme treatment reduces M6P/IGF2R expression in 
MCF-7 cells
To examine the ability of the ribozyme to reduce levels of
M6P/IGF2R mRNA in MCF-7 cells, total RNA was extract-
ed from cells infected with Ad-GFP/IGF2R-Rz or Ad-GFP,
and subjected to RT-PCR using M6P/IGF2R-specific prim-
ers. A primer specific for human -actin was added to a
parallel reaction to serve as an internal standard. Cells
were used 72 hrs post infection with average infection ef-
ficiency of 50–60% (for which a viral dose used had min-
imal cytotoxicity). The RT-PCR product of M6P/IGF2R
Figure 4
Effect of the ribozyme on the internalization of 125I-labeled IGF-II (A). Ribozyme-treated or control cells were incubated in
medium containing 125I-labeled IGF-II with or without excess unlabeled IGF-II. Following incubation, cells were washed and
cell-associated radioactivity was determined using a  counter. Determination of binding (B) and endocytosis (C) of M6P-con-
taining proteins in MCF-7 cells. The M6P-bearing enzyme -glucuronidase was used as a probe. The M6P-inhibitable binding
was measured by incubating saponin-peameabilized cells with -glucuronidase in the presence or absence of M6P. The M6P-
inhibitable uptake was determined by incubating cells with medium containing -glucuronidase in the presence or absence of
M6P. Following incubation, cells were washed extensively, and cell-associated -glucuronidase was measured fluorometrically.
Each point, the mean of three separate experiments (n = 3; *, p < 0.05; versus control).BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/18
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was 730 bp, and the -actin product was 285 bp. As
shown in Fig. 3, the Ad-GFP/Rz-IGF2R-infected cells ex-
hibit a significantly lower level of M6P/IGF2R mRNA than
Ad-GFP-infected cells, with a reduction of about 40%.
There was no significant difference in the level of M6P/
IGF2R mRNA between Ad-GFP-infected cells and unin-
fected cells (data not shown); indicating that infection
with the adenovirus itself did not alter the endogenous
M6P/IGF2R mRNA level. These results demonstrate that
the ribozyme was highly effective in suppressing M6P/
IGF2R expression in cultured MCF-7 cells.
Effect of ribozyme expression on the functional activity of 
M6P/IGF2R
To determine the effect of the ribozyme on the functional
activity of M6P/IGF2R, the binding and internalization of
exogenous 125I-IGF-II was measured in cells infected with
Ad-GFP/Rz-IGF2R or Ad-GFP. As shown in Fig. 4A, cells
infected with Ad-GFP/Rz-IGF2R had a corresponding re-
duction of ~40% in 125I-IGF-II internalization when com-
pared with control cells (infected with Ad-GFP). We also
examined the effect of the ribozyme on the M6P-binding
activity of the M6P/IGF2R using the M6P-bearing lyso-
somal enzyme, -glucuronidase, as a probe. The results
showed that the maximal M6P-binding capacity of MCF-
7 cells treated with the ribozyme was about 39% less than
that of controls (Fig. 4B). Furthermore, we assessed the
ability of MCF-7 cells to internalize exogenous -glucuro-
nidase after treatment with ribozyme. Similarly, the M6P-
inhibitable endocytosis of -glucuronidase by ribozyme-
treated MCF-7 cells was about 38% less than that of con-
trol cells (Fig. 4C). These results confirm that the number
of functional M6P/IGF2R in ribozyme-treated cells was re-
duced.
Effects of M6P/IGF2R-ribozyme expression on prolifera-
tion of MCF-7 cells
We examined the effects of ribozyme-induced M6P/
IGF2R down-regulation on the growth of cultured MCF-7
cells. We did not observe any difference in cell growth be-
tween GFP-only infected and non-infected cells (data not
shown). Thus, all subsequent experiments were per-
formed using GFP-only infected cells as control. Assess-
ment of cell proliferative activity by MTT assay and
counting of viable cells (data not shown) indicated that
the number of MCF-7 cells in ribozyme-expressing cul-
tures was significantly higher than that in control cultures
(Fig. 5). These differences in growth pattern and cell
number were even more significant when the cultures
were treated with exogenous IGF-II (50 ng/ml, supple-
mented to culture medium) (Fig. 5). These results suggest
that decreasing M6P/IGF2R expression by the ribozyme
Figure 5
Effects of the ribozyme on the proliferation of MCF-7 cells.
Cells were infected with Ad.GFP/IGF2R-Rz or Ad.GFP
treated with or without IGF-II and then analyzed by MTT
assay. Each point, the mean of three separate experiments (n
= 3; *, p < 0.05; **, p < 0.01 versus control).
Figure 6
Effects of the IGF2R ribozyme on the apoptosis induced by
TNF in MCF-7 cells. Cells were infected with Ad.GFP (con-
trol, left panels) or Ad.GFP/Rz-IGF2R (right panels). 72 hrs
post infection, cells were treated with TNF for one day and
then cell death was examined using a fluorescence micro-
scope. Upper panels: Cells were stained with Hoechst dye for
nuclei and observed under 480 nm blue-fluorescent light. The
bright blue spots are the nuclei of apoptotic cells. Lower pan-
els: Cells were stained with Propidium Iodide dye for nuclei
and observed under 565 nm red-fluorescent light. The red
spots are the nuclei of dead cells.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/18
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can enhance proliferation of human breast cancer MCF-7
cells via an IGF-II-related mechanism.
Effect of M6P/IGF2R-ribozyme expression on apoptosis of 
MCF-7 cells
We examined the effects of ribozyme expression on apop-
tosis of cultured MCF-7 cells. After treatment with TNF, as
shown in Fig. 6, a large number of control cells underwent
apoptosis, as indicated by morphological changes (small
round shape) and bright blue nuclear staining. There were
significantly more apoptotic cells in control cultures than
in cultures expressing the Ad-GFP/IGF2R-Rz. Accordingly,
the number of viable cells, as measured by MTT analysis,
in cultures infected with Ad-GFP/IGF2R-Rz was signifi-
cantly (about 40%) higher than in cultures infected with
Ad-GFP (Fig. 7A). The number of apoptotic cells, as meas-
ured by the cell death ELISA assay, in cultures infected
with Ad-GFP/IGF2R-Rz was significantly (about 36%)
lower than in cultures infected with Ad-GFP (Fig. 7B).
These results are consistent with the hypothesis that de-
creasing M6P/IGF2R expression by ribozyme treatment
can reduce cell apoptosis.
Discussion
A growing body of genetic evidence suggests that the M6P/
IGF2 receptor is involved in carcinogenesis [15–29]. How-
ever, direct evidence of a growth-regulatory activity for
M6P/IGF2R is lacking. In this study, using ribozyme tech-
nology, we demonstrate an association of decreased ex-
pression and function of the M6P/IGF2R with increased
cell proliferation and decreased susceptibility to TNF-in-
duced apoptosis in human breast cancer MCF-7 cells. Ex-
pression of the ribozyme targeted against the M6P/IGF2
receptor in MCF-7 cells resulted in down-regulation of
M6P/IGF2R expression, as measured by RT-PCR, and
M6P/IGF2R function, indicated by a decrease in internal-
ization of 125I-IGF-II, and -glucuronidase binding and
endocytosis. Although we have not ruled out a RNAi effect
in cells, the observed effects are likely the consequence of
the specific cleavage of IGF2R mRNA by the ribozyme we
used.
MTT analysis and viable cell counts showed that ri-
bozyme-mediated down-regulation of M6P/IGF2R also
resulted in increased cell proliferation. Noticeably, the ef-
fect of ribozyme expression on cell growth was more ap-
parent in the presence of IGF-II. This result suggests that
the proliferative effect of M6P/IGF2R down-regulation is
likely the result of unchecked IGF-II stimulation. Because
the M6P/IGF2R is believed to sequester and degrade IGF-
II [10], a decrease in M6P/IGF2R could result in decreased
degradation and hence increased bioavailability of IGF-II
to the IGF-I receptor, which mediates the growth-promot-
ing effect of IGF-II. Supporting evidence for the involve-
ment of IGF-II in the proliferative effect resulting from
loss of M6P/IGF2R function comes from studies of M6P/
IGF2R knock-out mice. M6P/IGF2R-null mice display glo-
bal hyperplasia that coincides with elevated levels of IGF-
II. Most importantly, however, the lethal nature of an
M6P/IGF2R-null phenotype is reversed in an IGF-II-null
background [34]. Although we did not measure extracel-
lular levels of IGF-II, our results show that ribozyme-me-
diated down-regulation of M6P/IGF2R leads to a decrease
in IGF-II internalization, supporting the above possibility.
Our results also showed that M6P/IGF2R down-regula-
tion resulted in decreased sensitivity of MCF-7 cells to
TNF-induced apoptosis. Although we do not rule out the
potential contribution of the IGF-II pathway to this effect,
we would like to consider other potential M6P/IGF2R-de-
pendent mechanisms, such as lysosomal proteases and
TGF- signaling, that may directly affect cell sensitivity to
apoptosis. Recent evidence suggests that lysosomal en-
zymes, such as cathepsins B and D contribute to TNF-in-
duced apoptosis in vitro[35–38] and in vivo[39]. The M6P/
IGF2 receptor has been shown to be involved in binding,
transport and activation of lysosomal enzymes, including
cathepsins [12,13]. Therefore, it is possible that down-reg-
ulation of the M6P/IGF2R results in improper trafficking
and activation of cathepsins. This, in turn would elimi-
nate the apoptotic cascades triggered by these enzymes
under TNF stimulation and result in decreased sensitivity
of MCF-7 cells to apoptosis.
Figure 7
Effect of the ribozyme on the apoptosis induced by TNF in
the MCF-7 cells. Cells were infected with Ad.GFP/IGF2R-Rz
or Ad.GFP, treated with TNF and then cell viability was ana-
lyzed by MTT assay (A) and the apoptotic cells were assayed
using the cell death ELISA assay (B). Each point, the mean of
three separate experiments (n = 3; *, p < 0.05, versus con-
trol).BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/18
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It has also been shown that TNF stimulation involves the
activation of TGF- [40–42], a potent growth inhibitor for
many cell types and a ligand of M6P/IGF2R. In fact, acti-
vation of TGF- requires the binding of latent TGF- to the
M6P/IGF2 receptor [11]. Therefore, down-regulation of
M6P/IGF2R expression could also lead to a decreased bi-
oavailability of activated TGF-, thereby decreasing the
sensitivity of MCF-7 cells to the TGF- apoptotic pathway.
A detailed mechanism of the observed effect is currently
under investigation.
Conclusions
Our findings that ribozyme-mediated decrease in expres-
sion and functional activity of the M6P/IGF2R result in a
growth advantage for MCF-7 cells indicate that this recep-
tor acts as a negative regulator of cell growth. This is con-
sistent with previous observations that M6P/IGF2R
knockout mice displayed generalized increased growth
and cardiomygaly (resulting from cardiac myocyte hyper-
plasia) [34], and that antisense-mediated reduction of
M6P/IGF2R expression enhances tumorigenicity in JEG-3
cells [43]. Thus, loss or mutation of M6P/IGF2R may con-
tribute to development and progression of tumors via dif-
ferent pathways: by increasing the mitogenic activity of
IGF-II and decreasing the apoptotic signaling of TGF-
and lysosomal proteases. Further studies using various cell
types or using animals are needed to address this issue. Ri-
bozyme technology, as we show here, is a useful tool for
these studies.
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